Korea S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
3,130
KRW
+0.97%
-0.32%
+12.79%
Apr. 18
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
CI
Mar. 27
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 03:54 am EST
CrystalGenomics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 61.95 million compared to KRW 113.6 million a year ago. Net loss was KRW 3,963.09 million compared to KRW 771.14 million a year ago. Basic loss per share from continuing operations was KRW 63. Diluted loss per share from continuing operations was KRW 63.
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
Apr. 17
CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Mar. 26
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Mar. 17
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 15
CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
Jan. 24
CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc.
Dec. 13
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
23-10-11
CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD.
23-10-11
CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index
23-08-24
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-17
CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd.
23-06-01
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion.
23-03-29
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
22-11-21
CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
CrystalGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-16
CI
CrystalGenomics, Inc. announced that it has received KRW 5.7075 billion in funding from Kumho HT, Inc
22-08-07
CI
CrystalGenomics, Inc. announced that it expects to receive KRW 5.7075 billion in funding from Kumho HT, Inc
22-07-28
CI
CrystalGenomics, Inc. announced that it has received KRW 21.9999994 billion in funding
22-06-23
CI
CrystalGenomics, Inc. announced that it expects to receive KRW 21.9999994 billion in funding
22-06-12
CI
CrystalGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.
22-05-16
CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.
22-05-16
CI
CrystalGenomics, Inc.'s Equity Buyback announced on February 15, 2022, has expired with 688,603 shares, representing 1.01% for KRW 4,503.53 million.
22-05-15
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.
More about the company
1st Jan change
Capi.
+12.79% 174M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CRYSTALGENOMICS INVITES CO., LTD. 
